Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 3
1999 2
2000 6
2001 2
2002 4
2003 8
2004 7
2005 7
2006 5
2007 7
2008 7
2009 7
2010 5
2011 5
2012 3
2013 7
2014 6
2015 3
2016 1
2017 1
2018 5
2019 7
2020 3
2021 3
2022 2
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis.
Andrews CP, Mohar D, Salhi Y, Tantry SK. Andrews CP, et al. Ann Allergy Asthma Immunol. 2020 Feb;124(2):171-178.e2. doi: 10.1016/j.anai.2019.11.007. Epub 2019 Nov 15. Ann Allergy Asthma Immunol. 2020. PMID: 31734334 Free article. Clinical Trial.
BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). OBJECTIVE: To evaluate efficacy and safety of GSP301 in patients with seasonal AR (SAR). METHODS: In thi …
BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and m …
Efficacy and safety of GSP301 nasal spray in children aged 6 to 11 years with seasonal allergic rhinitis.
Prenner BM, Amar NJ, Hampel FC Jr, Caracta CF, Wu W. Prenner BM, et al. Ann Allergy Asthma Immunol. 2022 Nov;129(5):618-626.e2. doi: 10.1016/j.anai.2022.07.029. Epub 2022 Aug 1. Ann Allergy Asthma Immunol. 2022. PMID: 35926824 Free article. Clinical Trial.
BACKGROUND: GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate. OBJECTIVE: To evaluate the efficacy, safety, and tolerability of GSP301 in pediatric patients (aged 6 to <12 y …
BACKGROUND: GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticostero …
Pupil Diameter, Corneal Thickness, and Anterior Chamber Alterations Following Topical Olopatadine Hydrochloride 0.1%: A Single-Masked Randomized Controlled Clinical Study.
Çavdarli C, Topcu Yilmaz P. Çavdarli C, et al. J Ocul Pharmacol Ther. 2020 Sep;36(7):540-544. doi: 10.1089/jop.2020.0007. Epub 2020 Apr 3. J Ocul Pharmacol Ther. 2020. PMID: 32250190 Clinical Trial.
Purpose: Olopatadine hydrochloride 0.1% is one of the known primary topical treatments in ocular allergy. ...Conclusion: Olopatadine 0.1% does not lead to a significant change in corneal topography or anterior chamber parameters. ...
Purpose: Olopatadine hydrochloride 0.1% is one of the known primary topical treatments in ocular allergy. ...Conclusion: Ol …
Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety.
Sil A, Tripathi SK, Chaudhuri A, Das NK, Hazra A, Bagchi C, Islam CN. Sil A, et al. J Dermatolog Treat. 2013 Dec;24(6):466-72. doi: 10.3109/09546634.2012.750414. Epub 2013 Feb 3. J Dermatolog Treat. 2013. PMID: 23163959 Free article. Clinical Trial.
Routine hematological and biochemical tests and treatment-emergent adverse events were monitored for safety. RESULTS: Data from 54 subjects on olopatadine and 51 on levocetirizine were analyzed for effectiveness. UAS and TSS values declined significantly with both drugs ov …
Routine hematological and biochemical tests and treatment-emergent adverse events were monitored for safety. RESULTS: Data from 54 subjects …
Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.
Ayyappanavar S, Sridhar S, Kumar K, Jayanthi CR, Gangasagara SB, Rathod BLS, Preethi B, Mittal P. Ayyappanavar S, et al. Indian J Ophthalmol. 2021 Feb;69(2):257-261. doi: 10.4103/ijo.IJO_2083_20. Indian J Ophthalmol. 2021. PMID: 33463568 Free PMC article. Clinical Trial.
PURPOSE: To compare the efficacy and safety of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2%, and Bepotastine besilate 1.5% ophthalmic solutions in the treatment of allergic conjunctivitis. ...Each group was assigned to be treated with one of the three treatment …
PURPOSE: To compare the efficacy and safety of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2%, and Bepotastine besilate 1.5 …
Exploration of efficacy and mechanism of 0.05% cyclosporine eye drops (II) monotherapy in allergic conjunctivitis-associated dry eye.
Jiao X, Qi Y, Gao N, Zhang C, Zhao S, Yang R. Jiao X, et al. Eye (Lond). 2024 Apr;38(5):937-944. doi: 10.1038/s41433-023-02807-2. Epub 2023 Oct 30. Eye (Lond). 2024. PMID: 37904000 Clinical Trial.
The CsA group received 0.05% CsA eye drops (II) monotherapy four times daily. The control group received 0.1% olopatadine twice daily combined with 0.1% preservative-free artificial tears four times daily. ...And its efficacy is superior to 0.1% olopatadine combined …
The CsA group received 0.05% CsA eye drops (II) monotherapy four times daily. The control group received 0.1% olopatadine twice daily …
Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
Vogelson CT, Abelson MB, Pasquine T, Stephens DM, Gamache DA, Gross RD, Robertson SM, Yanni JM. Vogelson CT, et al. Allergy Asthma Proc. 2004 Jan-Feb;25(1):69-75. Allergy Asthma Proc. 2004. PMID: 15055565 Clinical Trial.
Results of these preclinical experiments conducted in guinea pigs indicated that olopatadine 0.2% (wt/vol) solution was significantly effective 24 hours after dosing. This concentration of olopatadine provided significantly more efficacy than Patanol (olopatadine …
Results of these preclinical experiments conducted in guinea pigs indicated that olopatadine 0.2% (wt/vol) solution was significantly …
Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2.
Fidler ML, Ogundele A, Covert D, Sarangapani R. Fidler ML, et al. J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):593-605. doi: 10.1007/s10928-018-9588-7. Epub 2018 Apr 21. J Pharmacokinet Pharmacodyn. 2018. PMID: 29680872 Free PMC article. Clinical Trial.
Olopatadine is an antihistamine and mast cell stabilizer used for treating allergic conjunctivitis. ...The number of allergy patients relieved with olopatadine 0.7% increased with higher baseline itching severity scores, when compared to olopatadine 0.2%....
Olopatadine is an antihistamine and mast cell stabilizer used for treating allergic conjunctivitis. ...The number of allergy patients …
Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis.
Gross GN, Berman G, Amar NJ, Caracta CF, Tantry SK. Gross GN, et al. Ann Allergy Asthma Immunol. 2019 Jun;122(6):630-638.e3. doi: 10.1016/j.anai.2019.03.017. Epub 2019 Mar 22. Ann Allergy Asthma Immunol. 2019. PMID: 30910440 Free article. Clinical Trial.
BACKGROUND: GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). OBJECTIVE: To evaluate the efficacy and safety of GSP301 in patients with seasonal allergic rhinitis (SAR). METHODS: In t …
BACKGROUND: GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate …
Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis.
Dudeja L, Janakiraman A, Dudeja I, Sane K, Babu M. Dudeja L, et al. Indian J Ophthalmol. 2019 Sep;67(9):1400-1404. doi: 10.4103/ijo.IJO_2112_18. Indian J Ophthalmol. 2019. PMID: 31436181 Free PMC article. Clinical Trial.
There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) for mild to moderate allergic conjunctivitis cases. ...
There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) for mild to moderate allergic co …
109 results